POLL: Which Recent FDA Update Was Most Exciting?


Click here to answer this week's poll.

Baricitinib FDA Approved to Treat Alopecia Areata
Dupilumab FDA Approved for AD Patients 6 months to 5 years
TMB-001 Granted FDA Breakthrough Therapy Designation
FDA Grants Priority Review for Dupilumab sBLA for Adults with Prurigo Nodularis
Tapinarof Cream 1% is FDA Approved
Related Videos
infectious disease
Related Content
© 2023 MJH Life Sciences

All rights reserved.